|
|
 | | | |
- close
- close
- close
- close
Benzinga
Jun 7
Comment
In a report published Friday, Wunderlich Securities analyst Greg Simpson downgraded the rating on Insulet Corporation (NASDAQ: PODD) from Buy to Hold, but reiterated the $28.00 price target.
In the report, Wunderlich Securities noted, “We are...
Benzinga
May 9
Comment
In a report published Wednesday, Barrington Research analyst Charley R. Jones downgraded the rating on Insulet Corporation (NASDAQ: PODD) from Outperform to Market Perform.
In the report, Jones noted, “PODD reported solid Q1/13 results with...
StreetInsider.com
May 6
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Guidance/Insulet+Corp.+%28PODD%29+Tops+Q1+EPS+by+1c/8308912.html for the full story.
StreetInsider.com
Feb 27
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Guidance/Insulet+Corp.+%28PODD%29+Tops+Q4+EPS+by+1c%3B+Sales+Guidance+Falls+Flat/8139239.html for the full story.
Benzinga
Feb 22
Comment
In a report published Friday, Canaccord Genuity reiterated its Buy rating on Insulet Corporation (NASDAQ: PODD), but slightly lowered its price target from $29.00 to $28.00.
Canaccord Genuity noted, “We are fine-tuning our model heading into...
Benzinga
Feb 15
Comment
In a report published Friday, J.P. Morgan reiterated its Overweight rating and $26.00 price target on Insulet Corporation (NASDAQ: PODD).
J.P. Morgan noted, “Insulet manufactures the OmniPod insulin pump system, which is a wireless,...
Benzinga
Jan 3
Comment
Insulet Corporation
(NASDAQ: PODD), the leader in tubeless insulin pump technology with
its OmniPod Insulin Management System, today announced the sale of
$85 million of its common stock pursuant to an underwriting agreement
with Canaccord Genuity...
Benzinga
Dec 21
Comment
In a report published Friday, Canaccord Genuity reiterated its Buy rating on Insulet Corporation (NASDAQ: PODD), and raised its price target from $24.50 to $29.00.
Canaccord Genuity noted, “We are reiterating our BUY rating on Insulet and...
Benzinga
Dec 17
Comment
Jefferies reiterated its Buy rating on Insulet (NASDAQ: PODD) and increased its price target from $23 to $25.
Jefferies said, "Insulet announced approval of the Eros pod this morning, bringing a close an almost two year 510k approval process....
Benzinga
Dec 17
Comment
Piper Jaffray raised its rating on Insulet Corporatio (NASDAQ: PODD) from Neutral to Overweight and increased its price target from $21 to $27.
Piper Jaffray commented, "We are raising our rating from Neutral to Overweight, following PODD's...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
TOP CONTRIBUTORS
Insulet (PODD) is competing against Mini Med, a division of Medtronic, for the insulin delivery system segment. The product has a needle which is inserted until an audible sound is heard, then the needle withdraws leaving behind a tethlon tube. Insuline is dripped from the pod into the body via the tube. When the pod is low on the solution, more is added. This avoids the nasty needle sticks many diabetics loath.
The pod can be worn many places on the body and has no major tubes of complicated computer readouts, vs. the typical insulin pump.
Often a physician asks the patient to try wearing the pod while it drips saline. Uptake is high afterwards as the pod is so comfortable.
Per the CEO, Duane Desisto, they may have a pump company burried in a pod company. Meaning that other drugs may be delivered via the pod.
References
| |||||||
